Threats and Opportunities Associated with the Implementation of Performance based Managed Entry Agreements in Slovakia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F22%3A00362196" target="_blank" >RIV/68407700:21460/22:00362196 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1109/EHB55594.2022.9991332" target="_blank" >https://doi.org/10.1109/EHB55594.2022.9991332</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1109/EHB55594.2022.9991332" target="_blank" >10.1109/EHB55594.2022.9991332</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Threats and Opportunities Associated with the Implementation of Performance based Managed Entry Agreements in Slovakia

Popis výsledku v původním jazyce

Slovakia has adopted an amendment to the of Act No. 363/2011 regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. The main objective of this qualitative research was to analyse the opinions, views and perceptions of Slovak stakeholders with regard to performancebased managed entry agreements (PB-MEA) as facilitated by the recent amendment. The survey was carried out on a sample of 12 stakeholders. The responses were analysed using MAXQDATA 2022 software. The results showed that there are some positive expectations towards the nation-wide implementation of the PBMEA such as better availability of medicines, emphasis on the patient. A significant number of threats were also identified such as procedural unpreparedness and problems with data availability.

Název v anglickém jazyce

Threats and Opportunities Associated with the Implementation of Performance based Managed Entry Agreements in Slovakia

Popis výsledku anglicky

Slovakia has adopted an amendment to the of Act No. 363/2011 regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. The main objective of this qualitative research was to analyse the opinions, views and perceptions of Slovak stakeholders with regard to performancebased managed entry agreements (PB-MEA) as facilitated by the recent amendment. The survey was carried out on a sample of 12 stakeholders. The responses were analysed using MAXQDATA 2022 software. The results showed that there are some positive expectations towards the nation-wide implementation of the PBMEA such as better availability of medicines, emphasis on the patient. A significant number of threats were also identified such as procedural unpreparedness and problems with data availability.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

50602 - Public administration

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Proceedings of 2022 E-Health and Bioengineering Conference (EHB)

ISBN

978-1-6654-8557-9

ISSN

—

e-ISSN

—

Počet stran výsledku

4

Strana od-do

—

Název nakladatele

Gr. T. Popa University of Medicine and Pharmacy

Místo vydání

Iasi

Místo konání akce

Iasi

Datum konání akce

17. 11. 2022

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

—